INO-4800 is Inovio's DNA vaccine candidate against SARS-CoV-2 and is composed of an optimized DNA plasmid, which is directly delivered into cells via a proprietary smart device.

The company cited universal eligibility and broad availability of COVID-19 vaccines in the U.S. as reasons why the DOD discontinued funding. Inovio executives said the decision does not affect other work that Inovio does with the U.S. government and is neither a result of the partial clinical hold nor a reflection of the data generated to date for the INO-4800 vaccine.

Inovio's COVID-19 vaccine is protective against variants of concern
Inovio has announced promising results from a study focusing on the human immune responses induced by its DNA vaccine candidate for COVID-19, INO-4800.

Inovio to develop COVID-19 DNA-encoded monoclonal antibodies
Inovio, along with a team of scientists from the Wistar Institute, AstraZeneca, the University of Pennsylvania, and Indiana University, has received a...

Inovio expands COVID-19 vaccine manufacturing with Kaneka
Inovio has brought Belgium-based Kaneka Eurogentec on board a global consortium of companies that will be manufacturing its DNA COVID-19 vaccine INO-4800,...

Inovio begins late phase clinical trials for COVID-19 vaccine
Inovio has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with the phase II segment of its phase II/III clinical trial...

FDA halts Inovio COVID-19 vaccine trial
The U.S. Food and Drug Administration (FDA) has halted Inovio's clinical trial of its COVID-19 vaccine candidate, INO-4800.